Clinical Trial Update: Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma [Phase 1]

View source ↗

Summary

This report covers a Phase 1 clinical trial evaluating a personalized neoantigen cancer vaccine in combination with pembrolizumab after rituximab in follicular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Personalized Neoantigen Cancer Vaccine
• Rituxan (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Follicular Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING